<DOC>
	<DOC>NCT01076153</DOC>
	<brief_summary>The investigators hypothesize that Klacid modified release (MR) shortens symptom recovery time in Thai patients with upper or lower respiratory tract infections.</brief_summary>
	<brief_title>Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Patients with upper or lower respiratory tract infection. Patient is male or female â‰¥ 18 years of age. Known hypersensitivity to or previously intolerant of macrolides. Illness severe enough to warrant hospitalization or parenteral therapy. Concomitant use of any of the following medications: Drugs metabolized by CYP3A isozyme: alprazolam, astemizole, carbamazepine, cilostazol, cisapride, cyclosporin, disopyramide, ergot alkaloids, lovastatin, methylprednisolone, midazolam, omeprazole, oral anticoagulants (e.g. warfarin), pimozide, quinidine, rifabutin, sildenafil, simvastatin, tacrolimus, terfenadine, triazolam and vinblastine. Drugs metabolized by other isozymes within CYP450 system: phenytoin, theophylline and valproate. Colchicine Digoxin Some antiretrovirals: zidovudine and ritonavir. Severe immunodeficiency and chronic disease conditions. Renal or hepatic impairment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Post-marketing observational study</keyword>
	<keyword>Upper or lower respiratory tract infection</keyword>
	<keyword>Klacid MR</keyword>
</DOC>